Lipid management in a japanese community: Attainment rate of target set by the Japan atherosclerosis society guidelines for the prevention of atherosclerotic cardiovascular diseases 2012

Journal of Atherosclerosis and Thrombosis

Volumn 24, Issue 3, 2017, Pages 338-345

  Tada, Hayato ^a   Kawashiri, Masa Aki ^a   Nohara, Atsushi ^a   Inazu, Akihiro ^b   Kobayashi, Junji ^c   Yasuda, Kenji ^d   Mabuchi, Hiroshi ^a   Yamagishi, Masakazu ^a   Hayashi, Kenshi ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

^d National Hospital Organization   (Japan)

Author keywords

JAS guideline 2012; LDL cholesterol; Specific health checkup

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; ATHEROSCLEROSIS; BODY MASS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; GOAL ATTAINMENT; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; JAPANESE (PEOPLE); MALE; MEDICAL EXAMINATION; MEDICAL SOCIETY; NORMAL HUMAN; PROTEINURIA; QUESTIONNAIRE; RISK ASSESSMENT; SMOKING; WAIST CIRCUMFERENCE; CARDIOVASCULAR DISEASES; MIDDLE AGED; PARTICIPATORY RESEARCH; PROTOCOL COMPLIANCE; RISK FACTOR; SECONDARY PREVENTION;

ADULT; AGED; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; COMMUNITY-BASED PARTICIPATORY RESEARCH; FEMALE; GUIDELINE ADHERENCE; HUMANS; LIPIDS; MALE; MIDDLE AGED; RISK FACTORS; SECONDARY PREVENTION; SOCIETIES, MEDICAL;

EID: 85014252307     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.36004     Document Type: Article

References (14)

1. Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, Kihara S, Kinoshita M, Maruyama C, Ohta T, Okamura T, Yamashita S, Yokode M, Yokote K; Japan Atherosclerosis Society: Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -2012 version. J Atheroscler Thromb, 2013; 20: 517-523
2. Teramoto T, Kashiwagi A, Ishibashi S, Daida H; Japan Lipid Guideline Attainment Program Investigators: Cross-sectional survey to assess the status of lipid management in high-risk patients with dyslipidemia: clinical impact of combination therapy with ezetimibe. Curr Ther Res Clin Exp, 2012; 73: 1-15
3. Teramoto T, Kawamori R, Miyazaki S, Teramukai S, Sato Y, Okuda Y, Shirayama M: Lipid and blood pressure control for the prevention of cardiovascular disease in hypertensive patients: a subanalysis of the OMEGA study. J Atheroscler Thromb, 2015; 22: 62-75
4. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A; Collaborators developing the Japanese equation for estimated GFR: Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis, 2009; 53: 982-992
5. Chronic Kidney Disease Prognosis Consortium: Association of estimated glomerular filtration rate and albumin-uria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet, 2010; 375: 2073-2081
6. Okamura T, Tanaka H, Miyamatsu N, Hayakawa T, Kadowaki T, Kita Y, Nakamura Y, Okayama A, Ueshima H; NIPPON DATA80 Research Group: The relationship between serum total cholesterol and all-cause or cause-specific mortality in a 17.3-year study of a Japanese cohort. Atherosclerosis, 2007; 190: 216-223
7. Mabuchi H, Kita T, Matsuzaki M, Matsuzawa Y, Nakaya N, Oikawa S, Saito Y, Sasaki J, Shimamoto K, Itakura H; J-LIT Study Group: Japan Lipid Intervention Trial. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholes- terolemia and coronary heart disease: secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J, 2002; 66: 1096-1100
8. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y; MEGA Study Group: Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet, 2006; 368: 1155-1163
9. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; Japan EPA lipid intervention study (JELIS) Investigators: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet, 2007; 369: 1090-1098
10. Wakasugi M, Kazama JJ, Narita I, Iseki K, Moriyama T, Yamagata K, Fujimoto S, Tsuruya K, Asahi K, Konta T, Kimura K, Kondo M, Kurahashi I, Ohashi Y, Watanabe T: Association between combined lifestyle factors and non-restorative sleep in Japan: a cross-sectional study based on a Japanese health database. PLoS One, 2014; 9: e108718
11. Tsuruya K, Yoshida H, Nagata M, Kitazono T, Hirakata H, Iseki K, Moriyama T, Yamagata K, Yoshida H, Fujimoto S, Asahi K, Kurahashi I, Ohashi Y, Watanabe T: Association of the triglycerides to high-density lipoprotein cholesterol ratio with the risk of chronic kidney disease: analysis in a large Japanese population. Atherosclerosis, 2014; 233: 260-267
12. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culle-ton B, Hamm LL, McCullough PA, Kasiske BL, Kele-pouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation, 2003; 108: 2154-2169
13. Hopkins PN, Defesche J, Fouchier SW, Bruckert E, Luc G, Cariou B, Sjouke B, Leren TP, Harada-Shiba M, Mabuchi H, Rabès JP, Carrié A, van Heyningen C, Car-reau V, Farnier M, Teoh YP, Bourbon M, Kawashiri MA, Nohara A, Soran H, Marais AD, Tada H, Abifadel M, Boileau C, Chanu B, Katsuda S, Kishimoto I, Lambert G, Makino H, Miyamoto Y, Pichelin M, Yagi K, Yamagishi M, Zair Y, Mellis S, Yancopoulos GD, Stahl N, Mendoza J, Du Y, Hamon S, Krempf M, Swergold GD: Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclo-nal Antibody. Circ Cardiovasc Genet, 2015; 8: 823-831
14. Mabuchi H, Nohara A, Noguchi T, Kobayashi J, Kawashiri MA, Tada H, Nakanishi C, Mori M, Yamagishi M, Inazu A, Koizumi J; Hokuriku FH Study Group: Molecular genetic epidemiology of homozygous familial hypercholesterolemia in the Hokuriku district of Japan. Atherosclerosis, 2011; 214: 404-407